China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving approval from the Hainan Medical Products Administration for its poly-l-lactic collagen stimulators Lanluma V and X as clinically urgent medical devices for designated use in the Arsmo (Hainan) Aesthetic Hospital in the Boao Lecheng Medical Tourism Pilot Zone. The product is used to increase the volume of sunken areas on the face and body, especially for correcting skin sunken areas.
Product Profile and Specifications
Lanluma is a regenerative medical aesthetic filler product from Sinclair. Compared with other physical fillers, Lanluma has the ability to stimulate collagen regeneration. The main component of Lanluma is poly-l-lactic acid (PLLA), which is biocompatible and biodegradable. It can be safely and effectively used for large-area filling and can provide a long-term filling effect lasting 18-24 months. Lanluma is divided into two different specifications: the V-type for filling smaller parts such as the face, upper arm, neck, neck shoulder, and chest triangle, and the X-type for filling larger parts such as the hip.
Global Availability and CE Certification
The product, which obtained a CE certification in 2020, is now available in 32 locations globally. The approval from the Hainan Medical Products Administration marks a significant milestone for Huadong Medicine in expanding its presence in the aesthetic medical device market, particularly in the Boao Lecheng Medical Tourism Pilot Zone.-Fineline Info & Tech
